Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib

Bone Marrow Transplant. 2019 May;54(5):762-764. doi: 10.1038/s41409-018-0370-7. Epub 2018 Oct 22.

Authors

Matthias A Fante¹, Ernst Holler², Barbara Schmidt^{3

4}, Daniel Wolff², Yvonne Ehrl⁵, Annelie Plentz³

Affiliations

¹ Department of Hematology and Oncology, Internal Medicine III, University Medical Center, Regensburg, Germany. [email protected].
² Department of Hematology and Oncology, Internal Medicine III, University Medical Center, Regensburg, Germany.
³ Institute of Medical Microbiology and Hygiene, Department of Virology, University of Regensburg, Regensburg, Germany.
⁴ Institute of Clinical Microbiology and Hygiene, Clinical Virology and Infection Immunology, University Medical Center, Regensburg, Germany.
⁵ Department of Nephrology, Internal Medicine II, University Medical Center, Regensburg, Germany.

PMID: 30349038
DOI: 10.1038/s41409-018-0370-7

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Allografts
Graft vs Host Disease* / drug therapy
Graft vs Host Disease* / etiology
Graft vs Host Disease* / virology
Humans
Janus Kinase 1 / antagonists & inhibitors*
Janus Kinase 2 / antagonists & inhibitors*
Kidney Diseases* / drug therapy
Kidney Diseases* / etiology
Kidney Diseases* / virology
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy
Leukemia, Myeloid, Acute / virology
Male
Middle Aged
Nitriles
Peripheral Blood Stem Cell Transplantation
Polyomavirus Infections* / drug therapy
Polyomavirus Infections* / etiology
Polyomavirus*
Pyrazoles / pharmacology*
Pyrimidines
Unrelated Donors

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
JAK1 protein, human
JAK2 protein, human
Janus Kinase 1
Janus Kinase 2